Merck-Moderna mRNA melanoma vaccine hits Phase 3 RFS and DMFS

By Patrick Lancier

TL;DR — On Wednesday 19 August 2026 Merck and Moderna said an experimental individualized mRNA vaccine plus KEYTRUDA met late-stage endpoints in resected advanced melanoma. Merck, at 6:45 a.m. EDT, named the trial: Phase 3 INTerpath-001, intismeran autogene (V940 / mRNA-4157), 1,137 patients randomised 2:1, completely resected stage IIB-IV disease, NCT05933577. Primary recurrence-free survival and key secondary distant metastasis-free survival were met at a pre-specified interim analysis. France 24 / AFP, at 14:11, quotes the joint statement as the first positive Phase 3 readout for an mRNA-based cancer therapy, and stresses that no numerical data were published. The study continues for overall survival. This is not an approval. It is not a cure. It is not a Phase 3 hazard ratio.

What INTerpath-001 met — and what Wednesday did not quantify

Merck’s wording is specific. The combination met the primary RFS endpoint and the key secondary DMFS endpoint. It is described as the first positive Phase 3 for an individualized neoantigen therapy and for an mRNA-based cancer therapy, and as the first Phase 3 with a clinically meaningful improvement over KEYTRUDA alone in adjuvant resected melanoma. Safety was called consistent, with no new signals. AFP, relaying the same announcement, says the KEYTRUDA combination improved recurrence-free survival statistically significantly versus KEYTRUDA alone, in more than 1,100 people, without a table. Those two registers — clinically meaningful, statistically significant — are not a hazard ratio. No Phase 3 HR, median, or death count from the trial appears in these sources. None is invented here.

The 49% reduction in recurrence or death (HR=0.51; 95% CI 0.294-0.887) and the 59% reduction in distant metastasis or death (HR=0.411; 95% CI 0.200-0.843) sit in the same Merck release under a different heading: KEYNOTE-942, Phase 2b, five-year data at ASCO 2026. They are not INTerpath-001. Treating 49 and 59 as Wednesday’s Phase 3 result would mis-assign the year. Epidemiology in the same file is also not a trial event: labs, via AFP, put melanoma at more than 330,000 new cases worldwide in 2022; Merck estimates about 112,000 US cases and over 8,500 deaths in 2026; CNBC notes melanoma is about 1% of skin cancers but the large majority of skin-cancer deaths.

Regulators, overall survival, and what is not an approval

AFP says the companies will present the data at a medical congress and start steps with authorities toward approval. That is an intention, not a licence. CNBC writes that it is unclear when they plan to submit US applications. Dean Li, Merck Research Labs, told Squawk Box they will likely start talking to regulators about treatment and safety in the next few months. Bancel called it a big moment for medicine, a big moment for patients. A big moment is a quote. It is not a marketing authorization. Merck and CNBC both say the study continues for overall survival. An OS curve is not what Wednesday published.

The patient population in these pieces is adjuvant: surgery already done, stage IIB-IV, vaccine plus KEYTRUDA versus KEYTRUDA alone. It is not described here as a substitute for KEYTRUDA, and not as a first-line unresectable metastatic trial. Wednesday’s public file is a dual endpoint met at interim, a safety line with no new signals, and an OS follow-up that is still running.

Two market prints — premarket Reuters and the CNBC session — not one close

Reuters, via Boursier at 15:06 on 19 August 2026, is labelled here as premarket only: Moderna +60% to $103.60, Merck +7.5% before the open. CNBC’s session figures are different objects: Moderna soared about 177%, Merck climbed more than 12% Wednesday. CNBC also places market caps entering Wednesday at around $333 billion for Merck and near $25 billion for Moderna. Those caps are entry figures, not a close. No source in this file publishes a single closing price that reconciles 60% with 177%. This article does not mint one. The $103.60 print belongs to Reuters premarket. It does not belong, in these pieces, to CNBC’s about-177% session move.

The equity reaction is a reaction to a qualitative Phase 3 hit — RFS and DMFS met, no public Phase 3 HR, OS still open. Mixing the two prints, or pasting KEYNOTE-942’s 49/59 onto INTerpath-001, or calling Wednesday an approval, would be a sourcing error. The English record of 19 August 2026 stops before those steps. So does this article.

FAQ

Did the companies publish Phase 3 numbers on Wednesday?

No. France 24 / AFP says the joint statement reported a statistically significant RFS improvement versus KEYTRUDA alone without numerical data. This article does not invent a Phase 3 hazard ratio.

What did INTerpath-001 meet?

Merck: primary recurrence-free survival (RFS) and key secondary distant metastasis-free survival (DMFS) at a pre-specified interim analysis. 1,137 patients randomised 2:1, NCT05933577, completely resected stage IIB-IV melanoma.

Are the 49% and 59% figures from Phase 3?

No. Merck attaches them to KEYNOTE-942, a Phase 2b five-year update at ASCO 2026: 49% reduction in recurrence or death (HR=0.51; 95% CI 0.294-0.887) and 59% in distant metastasis or death (HR=0.411; 95% CI 0.200-0.843).

Is this an approval, or a cure?

No. AFP: the companies will present data at a medical congress and start steps with authorities toward approval. CNBC: unclear when they plan to submit US applications. Dean Li told Squawk Box they will likely start talking to regulators about treatment and safety in the next few months. The study continues for OS.

How should the two stock prints be read?

Separately. Reuters via Boursier, 19 August 2026 15:06, is premarket only: Moderna +60% to $103.60, Merck +7.5% before the open. CNBC session: Moderna soared about 177%, Merck climbed more than 12% Wednesday. Caps entering Wednesday: Merck around $333 billion, Moderna near $25 billion. No single close reconciling 60% and 177% is published here.

Sources

By Patrick Lancier

Merck-Moderna mRNA melanoma vaccine hits Phase 3 RFS and DMFS